Afrin Rahman Juthy

Ms. Afrin Rahman Juthy

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Shahad Saif KhandkerShahad Saif Khandker
Shahad Saif Khandker
APAlif Hasan Pranto
Alif Hasan Pranto
AJAfrin Rahman Juthy
Afrin Rahman Juthy
MZMariam Zaman
Mariam Zaman
ASArgha Sarkar
Argha Sarkar
A. N. M. Mamun-Or-RashidA. N. M. Mamun-Or-Rashid
A. N. M. Mamun-Or-Rashid
Background: Hematopoietic stem cell transplantation (HSCT) is a widely utilized subtype of transplantation employed in various malignant and non-malignant diseases, particularly when conventional treatments or therapeutics prove ineffective. Despite the frequent occurrence of post-transplantation lymphoproliferative disease (PTLD) in patients undergoing HSCT, no comprehensive global prevalence rate has been established to date. Methodology: In this study, we selected 39 studies from 941 studies from three databases (i.e., PubMed, ScienceDirect, and Google Scholar) to identify the global prevalence rate of PTLD in HSCT patients. Results: The pooled prevalence was determined as 5.6% (95% CI: 5.0 to 6.3) and increased to 12.4% (95% CI: 10.2 to 14.7) after excluding outlier studies. The quality of the studies was also high. The prevalence of death cases among HSCT patients was determined as 0.6% (95% CI: 0.4 to 0.9). PTLD was most prevalent in allogenic HSCT (i.e., 5.6% (95% CI: 4.9 to 6.3)) and within the European region (i.e., 27.1% (95% CI: 21.4 to 32.8)). Among risk factors, HLA mismatch was reported in most of the studies. Conclusion: This study assessed and discussed the overall global prevalence of PTLD in HSCT patients, continent-based prevalence, and risk factors that can be helpful in finding the possible prevention mechanism of PTLD and implementing individualized treatment approaches based on the treatment availability during HSCT.

Verified
Journal Article
Open access
PDF file
Shahad Saif KhandkerShahad Saif Khandker
Shahad Saif Khandker
APAlif Hasan Pranto
Alif Hasan Pranto
AJAfrin Rahman Juthy
Afrin Rahman Juthy
MZMariam Zaman
Mariam Zaman
ASArgha Sarkar
Argha Sarkar
Md Asiful IslamMd Asiful Islam
Md Asiful Islam
Background: Hematopoietic stem cell transplantation (HSCT) is a procedure used in different malignant and non-malignant diseases. Although post-transplant lymphoproliferative disorder (PTLD) is infrequently observed in patients with HSCT, no study on the overall global incidence rate is available to date. Methodology: In this study, we selected 39 studies from 941 studies from three databases (i.e., PubMed, ScienceDirect, and Google Scholar) to identify the global incidence rate of PTLD in HSCT. Results: The pooled incidence was determined to be 5.6% (95% CI: 5.0 to 6.3) and rose further to 12.4% (95% CI: 10.2 to 14.7) after excluding outlier studies. The quality of the studies was high as well. PTLD was prevalent the most in allogenic HSCT (i.e., 5.6% (95% CI: 4.9 to 6.3)) and within the European region (i.e., 27.1% (95% CI: 21.4 to 32.8)). Among risk factors, human leukocyte antigen (HLA) mismatch was reported in most of the studies. Conclusions: This study assessed and discussed the overall global incidence of PTLD in HSCT patients, continent-based incidence, and risk factors that can be helpful in finding the possible prevention mechanism of PTLD and implementing individualized treatment approaches based on the treatment availability during HSCT.